Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader
If you want to know more about the Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader industry. More news about Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader, are being released. Follow us / contact us for more Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader information!
Revenue hit $242 million, up 96.2% y-o-y.Net profit reached $92 million, up 56.67% y-o-y.R&D investment stood at $23 million, up 85.72% y-o-y. Vazyme recently released the 2022 semi-annual report, revealing the robust growth in the first half of the year. Vazyme has been stepping up R&D efforts over
Our vision is to lead in biotechnology by driving innovation relentlessly, pursuing the highest standards in quality of products and services, and creating value for our customers.
English
简体中文